Log In
BCIQ
Print this Print this
 

Convivia

  Manage Alerts
Collapse Summary General Information
Company Horizon Pharma plc
DescriptionOral 4-methylpyrazole (4-MP)
Molecular Target Not available
Mechanism of ActionNA
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard Indication Metabolic (unspecified)
Indication DetailsTreat aldehyde dehydrogenase (ALDH2) deficiency
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$800.0M

$800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/25/2016

$800.0M

$800.0M

0

08/30/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today